Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events

dc.contributor.authorBongomin, Felix
dc.contributor.authorMaguire, Niamh
dc.contributor.authorMoore, Caroline B.
dc.contributor.authorFelton, Timothy
dc.contributor.authorRautemaa-Richardson, Riina
dc.date.accessioned2023-11-30T10:55:20Z
dc.date.available2023-11-30T10:55:20Z
dc.date.issued2018-12-13
dc.description.abstractBackground: Long-term oral triazole antifungal therapy is the cornerstone of man agement for patients with chronic pulmonary aspergillosis (CPA). Itraconazole is the first-line choice of treatment. Voriconazole, posaconazole or isavuconazole can be used as alternative treatments in case of resistance or intolerance. All of these can cause significant adverse drug reactions. Objectives: To evaluate how CPA patients tolerate voriconazole and isavuconazole after prior triazole therapy. Methods: We performed a retrospective observational study at the UK National Aspergillosis Centre. Medical records for all consecutive CPA patients started on isa vuconazole and voriconazole during an observation period of 12 and 6 months re spectively were analysed. Results: During this study period, 20 patients were started on isavuconazole and 21 patients on voriconazole. Adverse events were seen in 18 of 21 (86%) the patients in the voriconazole group and 12 of 20 (60%) in the isavuconazole group (P = 0.02). For those who developed adverse events to these agents, the rates of discontinuation of therapy were comparable (ie 10/18 [56%], voriconazole vs 8/12 [67%], isavucona zole; P = 0.54). Five (25%) patients in the isavuconazole group who were intolerant to other triazoles tolerated the standard dose of isavuconazole. Conclusions: Compared with isavuconazole, adverse events were significantly higher in CPA patients commenced on voriconazole. Isavuconazole may be an option for those patients who are intolerant to other triazoles.en_US
dc.identifier.citationBongomin, F., Maguire, N., Moore, C. B., Felton, T., & Rautemaa‐Richardson, R. (2019). Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. Mycoses, 62(3), 217-222.en_US
dc.identifier.otherDOI: 10.1111/myc.12885
dc.identifier.urihttps://hdl.handle.net/20.500.14270/410
dc.language.isoenen_US
dc.publisherMycosesen_US
dc.relation.ispartofseries;3
dc.subjectadverse events,en_US
dc.subjectchronic pulmonary aspergillosis,en_US
dc.subjectisavuconazole,en_US
dc.subjectvoriconazoleen_US
dc.titleIsavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse eventsen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Bongomin Felix_FOM_62.pdf
Size:
542.72 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: